Navigation Links
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Date:6/30/2008

are to secure adequate non-dilutive capital to fund the Company's operations for the foreseeable future and to retire the Company's outstanding convertible debt which matures in July 2009."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate under development for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About VANTAS

VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.

About SUPPRELIN LA

SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilize
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Indevus Announces Management Changes
2. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
3. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
4. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
7. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
8. Indevus Announces Allergan as New Partner for SANCTURA Brand
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Alfacell Receives NASDAQ Non-Compliance Notification
11. Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-...ttheNASDAQOMXconferenceonTuesday,December1stat1:45...tenvialiveaudiobroadcastovertheInternetavailableat...Userscanclickthe"Webcast"icontoaccessthisfile. ,...ifeScienceandHighTechnologycompany.Itschemicalandb...
(Date:11/24/2009)..., SANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/-...ompanyfocusedondevelopingandcommercializingnovelpa...onno,PresidentandChiefExecutiveOfficer,isscheduled...erence,tobeheldDecember1-2,2009atTheNewYorkPalaceH...higlieri,ChiefFinancialOfficer,willbeavailabletore...
(Date:11/24/2009)..., ,Primaryefficacyendpointhasbeenmetforpatientsw..., QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEter...),aglobalbiopharmaceuticalcompanyfocusedonendocrin...datafromaPhase2studywithitstargetedcytotoxicpeptid...advancedorrecurrentendometrialcancer.Inapersonaliz...
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...euticals,Inc. (Nasdaq: CADX ), a biopharmaceutica...ommercializing proprietary product candidates prin...ounced that it completed its,previously announced ...llion shares of common stock at a price of $5.34 p...The proceeds from the offering will enable us to c...
...eutics, Inc., a,privately held ophthalmic-focused ... has entered into an exclusive licensing agreement...worldwide rights to develop and,market topical oph...oprietary anti- inflammatory agent norketotifen., ...220/CLW064LOGO ), "This agreement represents yet...
...ntures, specializing,in seed and early-stage inves...today announced the expansion of the firm,s invest..., PhD, as Venture Partner. 5AM Ventures,also annou...ociates, Kevin,M. Forrest, PhD, and R. Andrew McMi... have been with the 5AM team since early 2005. Car...
Other Biology Technology:Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering 2Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering 3Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases 25AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 25AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal 3
(Date:11/26/2009)...pressive antlers, red deer have been caught in the...lers are much more than decorative. They are letha... John Currey, from The University of York, UK, has...ne for over half a century and has become fascinat...a long-standing collaboration with Tomas Landete-C...
(Date:11/26/2009)...November 2009 What are the bare essentials of lif...ce a cell that can survive on its own? Can we desc...nd how an entire organism functions as a system? T...s in a partnership between the European Molecular ...and the Centre de Regulacio Genmica (CRG) in Barce...
(Date:11/25/2009)...ia don,t have easy lives. In addition to mammalian...atural enemies called bacteriophages, viruses that..., Still, bacteria and another class of microorga...environments such as deep-sea volcanic vents) mana... a built-in defense system that helps protect them...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Male seahorses like big mates 9136 1Male seahorses like big mates 9136 2Hormone clue to root growth 9134 1Hormone clue to root growth 9134 2Journal of Vascular and Interventional Radiology 3A New patient radiation safety guidelines 9132 1Journal of Vascular and Interventional Radiology 3A New patient radiation safety guidelines 9132 2Journal of Vascular and Interventional Radiology 3A New patient radiation safety guidelines 9132 3
...veling migratory moths may hitch a ride on the win...urrent Biology, a Cell Press publication, confirm...us report also in Current Biology offered the fi...icated internal compass, sailing on favorable wind...in a matter of days. Now, the research team that b...
...I When it comes to embryo formation in the lowly ...eads to enhanced developmental precision, accordin...from Cincinnati Children,s Hospital Medical Center...roductive biology may seem insignificant, one day ...cause the study provides new information about how...
... Calif.-- The transportation of antibodies from a ...opment of that child,s nascent immune system. Thos...nta before birth or via breast milk after birth, h...nd may influence the later occurrence of autoimmun...ia Institute of Technology (Caltech) have revealed...
Other Biology News:Migratory moths may hitch their rides, but they're anything but drifters 2Scientists trace molecular origin of proportional development 2Scientists trace molecular origin of proportional development 3Caltech biologists spy on the secret inner life of a cell 2Caltech biologists spy on the secret inner life of a cell 3
...0 contains 400 unique human proteins on a 1x3 inch...a cross section of all cellular proteins, are arra...itional control proteins and a specific chip layou...NIchip protein microarrays are high-density protei...
...0 contains 400 unique human proteins on a 1x3 inch...all extracellular proteins (EP) according to Gene ...ate for high-quality results. Additional control p...validity and reproducibility., UNIchip protein mic...
...s are E.Coli glycerol stocks contained in standard...cDNA clones with approximately 5,000 clones per pl... plate well, the corresponding subplate is screene...ve well(s). Cells from a positive well are then pl...
...ed Reticulocyte Lysate Systems(a,b,c,d) offer rese...nslations: a single-tube, coupled transcription/tr...implify the process and reduce the time required t...bbit reticulocyte lysate translations (1) commonly...
Biology Products: